Skip to main content
Premium Trial:

Request an Annual Quote

Karo Bio Selects Elsevier's Reaxys to Support Medicinal Chemistry Projects

Premium

Elsevier said this week that Karo Bio has licensed its Reaxys suite to help its chemists identify and prioritize viable drug compounds for further research and development.

Specifically, Karo's chemists are using Elsevier's Reaxys and Reaxys Medicinal Chemistry solutions. These tools give researchers access to biological and chemistry data from periodicals, peer-reviewed journal articles, and patents.

The financial details of the agreement were not disclosed.

Elsevier's Reaxys portfolio is one of several products for drug discovery and development offered by the company's life science solutions business. Other tools in the unit include ScienceDirect, Scopus, TargetInsights, Pathway Studio, PharmaPendium, QUOSA, and Embase.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.